Core Viewpoint - The recent bullish "outside day" candle on April 30 indicates a potential for upward price movement in the S&P 500 Index (SPX), supported by historical trends and current market sentiment [4][5]. Market Sentiment and Technical Analysis - The SPX closed above its year-end 2024 level for the first time since February 28, suggesting a shift in market dynamics [3]. - A significant gap above resistance levels was observed, driven by positive developments in U.S.-China trade talks, which traders did not fully discount [5]. - The SPX's recent rally has left it "overbought" according to the 14-day Relative Strength Index (RSI), indicating potential caution for future movements [6]. Resistance and Support Levels - Key resistance levels for the SPX include the 6,000 mark and just below 6,150, which is the all-time high from February [7][8]. - Potential support levels are identified at 5,882 (2024 close), 5,783 (Election Day close), and the 200-day moving average at 5,760 [15]. Market Dynamics and Investor Behavior - Low put open interest suggests reduced hedging among money managers, who are increasingly looking at overseas markets and alternative assets like gold [2]. - A notable decrease in the buy-to-open put/call volume ratio indicates a shift in sentiment among equity option buyers, moving closer to levels that have historically preceded market weakness [13][14].

Group 1 - Inogen (INGN) has experienced a significant decline of 15.7% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for INGN is currently at 28.33, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that INGN will report better earnings than previously predicted, with a consensus EPS estimate increase of 18.6% over the last 30 days [6] Group 2 - INGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [7]

Core Viewpoint - Surrozen, Inc. (SRZN) has experienced significant selling pressure, resulting in a 29.7% decline over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - SRZN's current RSI reading is 27.4, suggesting that the heavy selling may be exhausting, which could lead to a price rebound [5] Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for SRZN, resulting in a 69.2% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6] - SRZN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7]

Core Viewpoint - Exelon (EXC) has experienced significant selling pressure, declining 9.2% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by analyst expectations of better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - EXC's current RSI reading is 28.78, suggesting that the heavy selling may be exhausting itself and a trend reversal could occur soon [5]. - The RSI helps investors identify potential entry opportunities when a stock is undervalued due to unwarranted selling pressure [3]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for EXC will improve, with a 1.3% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. - EXC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Allogene Therapeutics (ALLO) has experienced a significant decline of 31.9% over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Stock Performance and Technical Indicators - ALLO's stock has been under heavy selling pressure, leading to an RSI reading of 25.87, indicating it is oversold [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2]. - Stocks oscillate between overbought and oversold states, and an oversold condition may present entry opportunities for investors anticipating a rebound [3]. Group 2: Analyst Sentiment and Earnings Estimates - There is a strong consensus among sell-side analysts to raise earnings estimates for ALLO, resulting in a 0.4% increase in the consensus EPS estimate over the last 30 days [7]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [7]. - ALLO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) has experienced significant selling pressure, resulting in a 15.6% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - TARS has an RSI reading of 29.83, suggesting that the heavy selling may be exhausting, potentially leading to a price rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for TARS by 19.5% over the last 30 days, indicating a positive trend that typically correlates with price appreciation [6] - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [7]

A downtrend has been apparent in New Jersey Resources (NJR) lately with too much selling pressure. The stock has declined 5.3% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

Core Viewpoint - Investors should focus on pharmaceutical stocks that are currently trading at extremely oversold levels, as indicated by the Relative Strength Index (RSI), which can signal potential rebounds [1][13]. Group 1: Sarepta Therapeutics - Sarepta Therapeutics has an RSI of 22, indicating extreme oversold conditions, and has seen its stock price drop over 40% following an earnings miss [2][3]. - The 12-month stock price forecast for Sarepta is $131.22, suggesting a potential upside of 262.48% from the current price of $36.20 [2]. - Analysts, including those from Wells Fargo, maintain a Buy rating and are optimistic about Sarepta's long-term pipeline, particularly its FDA-approved gene therapy for Duchenne muscular dystrophy [3][4]. Group 2: Krystal Biotech - Krystal Biotech's RSI has risen to 33, indicating a recovery from oversold levels, with a recent stock price of $134.53 [5][6]. - The 12-month stock price forecast for Krystal is $218.63, representing a potential upside of 62.51% [5]. - Analysts remain bullish on Krystal, with Guggenheim reiterating a Buy rating and a price target of $189, indicating nearly 40% upside potential [7][8]. Group 3: Lantheus Holdings - Lantheus Holdings has an RSI of 28, showing signs of being oversold after a 25% drop following an earnings miss [9][10]. - The 12-month stock price forecast for Lantheus is $132.67, suggesting a potential upside of 68.04% from the current price of $78.95 [9]. - Truist Financial has reiterated a Buy rating with a price target of $117, indicating more than 45% upside potential, supported by the company's strong product portfolio [11][10].

Sera Prognostics, Inc. (SERA) has been beaten down lately with too much selling pressure. While the stock has lost 30.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Core Viewpoint - AZUL has experienced significant selling pressure, declining 57.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory, supported by positive earnings forecasts from Wall Street analysts [1]. Group 1: Stock Performance - AZUL's stock has declined 57.1% in the last four weeks, indicating substantial selling pressure [1]. - The stock's Relative Strength Index (RSI) is currently at 23.35, suggesting it is oversold and may soon experience a trend reversal [5]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that AZUL will report better earnings than previously predicted, with the consensus EPS estimate increasing by 8.3% over the last 30 days [7]. - AZUL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].